Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Conditions:   Ovarian Cancer;   Ovarian and Fallopian Tube Cysts and Neoplasms;   Neoplasms by Site;   Neoplasms;   Genital Neoplasms, Female;   Urogenital Neoplasms;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Carcinoma, Ovarian Epithelial;   Ovarian  Diseases;   Adnexal Diseases;   Genital Diseases, Female;   Carcinoma;   Anlotinib;   PARP Inhibitors;   BRCA1 Mutation;   Angiogenesis;   Antineoplastic Agents;   BRCA2 Mutation Interventions:   Drug: Anlotinib;   Drug: Olaparib Sponsor:   Xiaoxiang Chen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials